APP and Alzheimer disease: More importantly, complementary studies showed that SFN improved neurobehavioral deficits and decreased the load of Aβ in the AD transgenic mice model (APP/PS1) where treatment with SFN increased p75 neurotrophin receptor levels by reducing histone deacetylase 1 and 3 expressions [327].